Scientific Publications

Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

Publication TypeJournal Article
AuthorsLi, JZ, Chapman B., Charlebois P., Hofmann O., Weiner B., Porter AJ, Samuel R., Vardhanabhuti S., Zheng L., Eron J., Taiwo B., Zody MC, Henn MR, Kuritzkes DR, Hide W., ACTG A5262 Study Team, Wilson CC, Berzins BI, Acosta EP, Bastow B., Kim PS, Read SW, Janik J., Meres DS, Lederman MM, Mong-Kryspin L., Shaw KE, Zimmerman LG, Leavitt R., De La Rosa G., and Jennings A.
AbstractThe impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina and 454 for the detection of HIV-1 raltegravir-resistant MVs.
Year of Publication2014
JournalPloS one
Volume9
Issue3
Pagese90485
Date Published (YYYY/MM/DD)2014/01/01
DOI10.1371/journal.pone.0090485
PubMedhttp://www.ncbi.nlm.nih.gov/pubmed/24603872?dopt=Abstract